For patients with highly invasive and treatment‐resistant mesenchymal subtype GBM, combining TEFT with TGF‐β/C1R targeted inhibitors may synergistically suppress mesenchymal transition, enhancing treatment sensitivity and efficacy. This evidence concerns the gene TGFB1 and glioblastoma.